A Multicenter Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
Latest Information Update: 07 Feb 2025
At a glance
- Drugs Glovadalen (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms ATLANTIS
- Sponsors UCB Biopharma
- 06 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 15 Oct 2024 Planned End Date changed from 23 Dec 2024 to 14 Apr 2025.
- 15 Oct 2024 Planned primary completion date changed from 9 Dec 2024 to 27 Mar 2025.